Fortress Biotech (FBIO) got here out with a quarterly lack of $0.04 per share versus the Zacks Consensus Estimate of a lack of $0.14. This compares to lack of $0.19 per share a 12 months in the past. These figures are adjusted for non-recurring gadgets.
This quarterly report represents an earnings shock of 71.43%. 1 / 4 in the past, it was anticipated that this biopharmaceutical firm would submit a lack of $0.17 per share when it really produced a lack of $0.11, delivering a shock of 35.29%.
Over the past 4 quarters, the corporate has surpassed consensus EPS estimates 4 instances.
Fortress Biotech, which belongs to the Zacks Medical – Biomedical and Genetics trade, posted revenues of $17.84 million for the quarter ended June 2021, surpassing the Zacks Consensus Estimate by 29.11%. This compares to year-ago revenues of $9.46 million. The corporate has topped consensus income estimates two instances over the past 4 quarters.
The sustainability of the inventory’s rapid value motion primarily based on the recently-released numbers and future earnings expectations will principally rely upon administration’s commentary on the earnings name.
Fortress Biotech shares have misplaced about 2.8% because the starting of the 12 months versus the S&P 500’s achieve of 19%.
What’s Subsequent for Fortress Biotech?
Whereas Fortress Biotech has underperformed the market to date this 12 months, the query that involves traders’ minds is: what’s subsequent for the inventory?
There aren’t any simple solutions to this key query, however one dependable measure that may assist traders deal with that is the corporate’s earnings outlook. Not solely does this embody present consensus earnings expectations for the approaching quarter(s), but additionally how these expectations have modified these days.
Empirical analysis exhibits a robust correlation between near-term inventory actions and traits in earnings estimate revisions. Buyers can monitor such revisions by themselves or depend on a tried-and-tested score software just like the Zacks Rank, which has a formidable monitor document of harnessing the ability of earnings estimate revisions.
Forward of this earnings launch, the estimate revisions development for Fortress Biotech was unfavorable. Whereas the magnitude and course of estimate revisions might change following the corporate’s just-released earnings report, the present standing interprets right into a Zacks Rank #4 (Promote) for the inventory. So, the shares are anticipated to underperform the market within the close to future. You’ll be able to see the whole listing of at this time’s Zacks #1 Rank (Sturdy Purchase) shares right here.
Will probably be fascinating to see how estimates for the approaching quarters and present fiscal 12 months change within the days forward. The present consensus EPS estimate is -$0.15 on $16.65 million in revenues for the approaching quarter and -$0.55 on $60.42 million in revenues for the present fiscal 12 months.
Buyers ought to be conscious of the truth that the outlook for the trade can have a fabric influence on the efficiency of the inventory as effectively. By way of the Zacks Business Rank, Medical – Biomedical and Genetics is presently within the backside 22% of the 250 plus Zacks industries. Our analysis exhibits that the highest 50% of the Zacks-ranked industries outperform the underside 50% by an element of greater than 2 to 1.
5 Shares Set to Double
Every was handpicked by a Zacks knowledgeable because the #1 favourite inventory to achieve +100% or extra in 2021. Earlier suggestions have soared +143.0%, +175.9%, +498.3% and +673.0%.
Many of the shares on this report are flying below Wall Avenue radar, which gives an excellent alternative to get in on the bottom flooring.
At present, See These 5 Potential Dwelling Runs >>
Click on to get this free report
Fortress Biotech, Inc. (FBIO): Free Inventory Evaluation Report
To learn this text on Zacks.com click on right here.
Zacks Funding Analysis
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.